Share on LinkedInShare on LinkedIn

ARTICLE · 07 MAY 2026

Genetic Data And Artificial Intelligence Training Following Acquisitions: Emerging Litigation Risk And A Rapidly Expanding State Regulatory Landscape

Crowell & Moring LLP
Crowell & Moring LLP
Contributor
Crowell & Moring LLP

Crowell & Moring LLP

Crowell & Moring’s Doha office is a full service legal practice that serves as the firm’s regional...

View firm profile
Explore more from Crowell & Moring LLP

Several recent class actions filed against Tempus AI, Inc., a health care technology company that combines AI with molecular and clinical data to develop precision medicine services...

United StatesTechnology

What You Need to Know

  • Key takeaway #1

    Putative class actions are increasingly challenging the repurposing and commercialization of genetic data following acquisitions, particularly where AI training and downstream licensing are alleged.

  • Key takeaway #2

    The state genetic privacy landscape is expanding rapidly beyond the HIPAA baseline, with Illinois, South Dakota, Utah, California, and others advancing distinct frameworks with meaningful enforcement mechanisms.

  • Key takeaway #3

    De-identification is under active legal and scientific attack in the genetic data context and should not be relied upon as a standalone compliance strategy.

  • Key takeaway #4

    M&A diligence and integration planning should treat consent scope and state-law compliance as core deal considerations whenever a target holds genetic or genomic data assets that may be used by potential acquirors.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from